Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Topotecan

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven non-small cell lung cancer

• Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard radiotherapy indications)

• Measurable or evaluable disease

• Measurable disease defined as bidimensionally measurable lesion on physical exam or radiograph (CT or MRI acceptable)

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: 0-2

• Life expectancy: At least 12 weeks

• WBC at least 4,000/mm3

• Platelet count at least 100,000/mm3

• Bilirubin no greater than 1.5 mg/dL

• AST less than 3 times normal

• Alkaline phosphatase less than 3 times normal

• Creatinine no greater than 1.5 mg/dL

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• No more than 1 prior chemotherapy regimen allowed

• At least 4 weeks since prior chemotherapy and recovered

• No prior radiotherapy

• Recovered from toxic effects of any prior therapy